Research guide · Recovery

BPC-157
research guide

What this 15-amino-acid peptide is, what three decades of mostly animal research report, what the human evidence actually amounts to, and where regulators stand in November 2026.

Reading time9 min
ClassSynthetic pentadecapeptide
Evidence gradePreclinical

Written by 6AM Research · 18 Nov 2026. This guide summarises research. It is not medical advice.

BPC-157
35 of 36studies in a 2025 review were preclinical
Oct 2026 HHS policy on licensed compounding; not an approval
Short answerResearch guide · 9 min read · Updated 18 Nov 2026

BPC-157 is a pentadecapeptide, a chain of 15 amino acids. A 2025 systematic review of musculoskeletal studies found 35 of its 36 included studies were preclinical. The human studies are few and small, most had no control group, and the only randomised data are in conference abstracts. It is not an approved medicine in the US, and WADA names it in class S0.

Key takeaways

  • BPC-157 is a synthetic 15-amino-acid peptide, reported to be a fragment of a protein found in human gastric juice.
  • Most published research is in cells and animals: 35 of the 36 studies in a 2025 systematic review were preclinical.
  • Human evidence is limited to a few small studies, most without a control group. The only randomised, placebo-controlled data are in conference abstracts; no peer-reviewed randomised trial has been published.
  • In its 2026 review, FDA found no approved product containing it in any country, and WADA prohibits it in sport at all times.

01What is BPC-157?

A hand holding an unlabelled glass vial of white freeze-dried powder
What researchers use is made synthetically. Illustrative image, not a 6AM batch.

BPC-157 is a pentadecapeptide, a chain of 15 amino acids. It was first described in the early 1990s as a fragment of a protein, called BPC, reported to be found in human gastric juice. What researchers use is made synthetically; FDA’s 2026 review covered the free base and the acetate salt, and noted that most studies do not say which form they used.

02Has BPC-157 been studied in humans?

Cell studies
Extensive
Animal studies
Extensive
Human pilot / case series
Minimal
Controlled human trials
Abstracts only
Regulatory approval
None

A 2025 systematic review of musculoskeletal studies found 35 of its 36 included studies were preclinical; the one human study had no control group.

Source: Vasireddi et al., HSS J, 2025

03What mechanisms have cell and rodent studies proposed for BPC-157?

In 2026, FDA staff wrote that BPC-157’s molecular targets “have not been identified” and its mechanisms of action “remain poorly understood”. The mechanisms below are hypotheses from cell and rodent studies, not findings in people.

Gloved hands holding a cell-culture plate
1
Growth factors and their receptors

Higher expression reported in cell and rodent studies, including the growth-hormone receptor in cultured tendon cells.

2
New blood vessels

Signs of new blood-vessel growth (angiogenesis) reported in cell and rodent studies.

3
Nitric oxide

Effects on nitric-oxide production reported in rodent studies.

4
Inflammatory signals

Lower release or expression of inflammatory factors reported in cell and rodent studies.

5
Tendon-cell migration

In rat tendon cells and tissue pieces in the lab, more cell outgrowth and migration, with activation of the FAK–paxillin pathway (Chang 2011). That is not evidence of an effect in animals or people.

04How strong is the evidence on BPC-157?

Area studiedMain evidenceHuman dataGrade
Gut lining and ulcersRodent ulcer, colitis and fistula modelsRandomised data only in conference abstracts: a tolerability study and a colitis trial that FDA staff found inadequate to support efficacy or safetyPreclinical
Tendon and ligamentRodent transection and detachment modelsNone controlledPreclinical
Muscle injuryRodent muscle-injury modelsNone controlledPreclinical
Joint pain—One retrospective case series in knee pain, no control groupVery limited
BoneAnimal bone-injury modelsNonePreclinical

05What hasn't BPC-157 research shown?

Empty laboratory beakers and a petri dish on white

That effects in rodents translate to people.

No randomised, controlled human efficacy trial has been published as a full peer-reviewed paper; the only one is known from a 2005 conference abstract.

A characterised human safety profile.

FDA staff concluded that “there is insufficient clinical safety information to characterize the safety profile” of BPC-157.

Dose–response in animals.

FDA staff noted that dose–response relationships in the rodent gut and liver models “have not been established”.

How BPC-157 behaves in the human body.

FDA staff found no human pharmacokinetic data for most routes, and in the two studies that measured blood levels BPC-157 was not detected or mostly below the assay’s limit.

06Is BPC-157 an approved medicine? Status, Nov 2026

No. BPC-157 is not an approved medicine in the US, and in its 2026 review FDA found no approved product containing it in any country.

  1. Sep 2023FDA places BPC-157 in Category 2

    Listed in Category 2 of FDA’s interim compounding policies, the category for bulk substances that may present significant safety risks.

  2. 22 Apr 2026Out of Category 2

    Moved to FDA’s list of substances whose nominations were withdrawn by the nominators. HHS later noted that neither the placement nor the removal changed its status under section 503A.

  3. 23 Jul 2026Advisory committee votes in favour

    FDA’s Pharmacy Compounding Advisory Committee voted in favour of adding BPC-157 to the 503A bulks list. FDA’s drug centre had recommended against. The vote is advice, not a rule.

  4. 28 Oct 2026HHS enforcement-discretion policy

    HHS said it does not intend to act against state-licensed pharmacies, federal facilities and licensed physicians compounding BPC-157 acetate on a patient-specific prescription under ten conditions. The Federal Register notice calls it a draft; it is not binding and not an approval. Products sold as research chemicals are outside it.

  5. NowStill not an approved medicine

    BPC-157 is not an approved medicine in the US, and WADA names it in class S0. Dated record: Is BPC-157 legal?

07What should a BPC-157 COA show?

A certificate of analysis should let you answer these five questions.

The 6AM mark rendered in glass
1
Does the batch number match the vial?

A generic or undated COA proves nothing about the vial in front of you.

2
Was identity confirmed by mass spectrometry?

HPLC measures purity, not identity. Its molecular weight is 1419.5 g/mol (free base).

3
What is the HPLC purity, and at what wavelength?

Look for the chromatogram, not just a percentage.

4
Who ran the test?

A named lab can be looked up. If it claims accreditation, check that the test on the report is one the accreditation covers.

5
Was endotoxin screened?

Relevant for any material used in cell or animal work.

08Sources

  1. Vasireddi N, Hahamyan HA, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. doi:10.1177/15563316251355551. pubmed.ncbi.nlm.nih.gov/40756949/
  2. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: BPC-157-related bulk drug substances. Advisory committee briefing, 2026; read 18 Nov 2026. www.fda.gov/media/193343/download
  3. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol, 2011;110(3):774–780. PMID 21030672. pubmed.ncbi.nlm.nih.gov/21030672/
  4. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med, 2021;27(4):8–13. pubmed.ncbi.nlm.nih.gov/34324435/
  5. Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg, 2026;92(3). PMID 42885452. pubmed.ncbi.nlm.nih.gov/42885452/
  6. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 18 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-…
  7. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendices A and B. Policy document, 2026. hhs.gov returned 403 to our fetch on 18 Nov 2026; read on the Internet Archive capture of 15 Nov 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcemen…
  8. Federal Register 91 FR 68526, FR Doc. 2026-22192. Notice of availability: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Notice, 30 Oct 2026 (filed 28 Oct 2026); text read on govinfo 18 Nov 2026. www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.h…
  9. FDA. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Advisory committee calendar, content current 6 Aug 2026. www.fda.gov/advisory-committees/advisory-committee-calendar…
  10. World Anti-Doping Agency. Prohibited List 2026 (in force 1 Jan 2026) and Prohibited List 2027 (in force 1 Jan 2027). International Standard; both PDFs read 18 Nov 2026. www.wada-ama.org/en/prohibited-list

Questions about a source?

Write to 6AM Research about any study or document cited in this guide.

Write to us

Common questions

Is BPC-157 FDA-approved?

No. It is not an approved medicine in the US, and in its 2026 review FDA found no approved product containing it in any country. The July 2026 advisory vote and the October 2026 HHS policy concern compounding by licensed pharmacies on prescription; neither is an approval.

Is there good human evidence?

No. The human studies are few and small, most had no control group, and the only randomised data are in conference abstracts. A 2026 systematic review of the three full papers rated the certainty of the evidence “very low”.

Is BPC-157 prohibited in sport?

Yes. WADA’s Prohibited List names it in class S0, non-approved substances, prohibited at all times.

Further reading

Articles on this topic

Claims vs evidenceBPC-157 claims and the evidence: what studies measuredClaims about BPC-157 rest mostly on rat and cell studies. In people, the only randomised data are conference abstracts (checked 21 Nov 2026).11 min readIdentity and historyBPC-157 History: Origin, Names and RegulationBPC-157 history from Zagreb in 1992–93 to 2026: who described it, how it got its name and codes, how research grew, and its dated regulatory steps.11 min readComparisonBPC-157 vs GHK-Cu: Identity, Evidence and StatusBPC-157 and GHK-Cu side by side: what each peptide is, how each has been studied, and its US, UK, Australian and anti-doping status, dated Nov 2026.13 min readComparisonBPC-157 vs KPV: identity, evidence and legal statusBPC-157 has limited human data. FDA staff found none for KPV. Compare their identities, evidence, regulatory status, and sport rules.7 min readSport · WADAIs BPC-157 Banned in Sport? WADA S0 and Dates (2026)Yes. WADA has named BPC-157 in class S0 since 1 January 2022. The List text, what the Code says, how anti-doping bodies apply it, and what changes in…10 min readLegal status · AustraliaIs BPC-157 Legal in Australia? Poisons Standard (2026)BPC-157 has been Schedule 4, with possession controls, since 1 June 2024. The Poisons Standard text, the TGA’s reasons, the Act and 2026 enforcement.11 min readLegal status · UKIs BPC-157 Legal in the UK? Law, MHRA and Dates (2026)We found no UK law that names BPC-157, and medicines law still applies. The Human Medicines Regulations 2012, MHRA guidance, 2026 enforcement and…11 min readComparisonPDA peptide vs BPC-157: identity, evidence and statusNo paper, trial record or FDA list we found uses the name PDA. What a 2017 patent on BPC-157 salts, BPC-157’s record and regulators do and do not say.8 min readStudy explainerWho was in the BPC-157 studies: sex, age and exclusionsSix published studies gave BPC-157 to 118 people: who they were by sex and age, and whom four registered trials exclude. Checked 21 Nov 2026.9 min read
Written by 6AM Research. Drafted from the studies and regulator documents listed in the Sources section, where each one is linked; the page is dated. Editorial policy · How we check every page
Research guide · BPC-157Members see live batch certificates for BPC-157.
Request access